Beta Blockers Could Improve Outcomes in Carotid Artery Stenting

Original Title: Beta-blocker use is associated with lower stroke and death after carotid artery stenting. Reference: Tammman Obeid, et al. J Vasc. Surg. 2016;63:363-9.

Courtesy of Dr. Carlos Fava.

The latest trials on Carotid Artery Stenting (CAS) have shown significantly improved effectiveness. The use of drugs such as beta blockers (BB) have proved beneficial in some studies, though it remains controversial.

5263 patients undergoing CAS were analyzed; 2152 (40%) had never received BB, 259 (4%) received BB between 1 and 30 days prior stenting and 2837 (53.9%) had been receiving BB >30 days prior procedure.

The groups were similar, mean age was 68 and most of them were men.

At 30 days, death and stoke rate was 3.4% (minor stroke 1.5%, major stroke 0.9% and death 1.2%) and there were no MI cases. 40% of patients presenting major stroke died within 30 days after procedure. 22% presented post procedural hypotension, unrelated to the use of BB. Instead, hypertension requiring treatment was 9.9% and it was frequent between patients receiving BB between days 1 and 30; it was associated to a 3.4 fold increase in stroke/death incidence (OR 3.39; CI 95% 2.3-5.00; p<0.0001). Hemorrhagic stroke was 0.5%, increased 8 fold by post procedural hypertension.

The use of BB more than 30 days prior procedure was associated to a 34% reduction of stroke/death rate (OR 0.66; CI 95% 0.46-0.95; p<0.025).

Other predictors of stroke/death were age, diabetes, symptomatic lesions and post-procedural hypotension, whereas prior endarterectomy and the use of protection systems resulted protective.

Conclusion
Hypertension and hypotension that require treatment, are strongly associated with stroke and death after CAS. BB significantly reduce periprocedural stroke/death rates. To better assess the potential of these drugs in CAS calls for further prospective research.

Editorial Comment
This is a retrospective study but it includes a significant number of patients. It shows that a simple and low cost strategies can render considerable benefits in harsh events, in addition to experience and rigorous hemodynamic control, which are essential to achieve better results.

Further randomized studies are necessary to find out who will benefit most from the use of BB.

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....